Class action lawsuits are frequently filed against pharmaceutical companies for serious complications and harm caused by prescription medications. This article lists the top class action drug lawsuits pending in courts throughout the United States in 2017.
Filed Under: Onglyza News – Lawsuits, Settlements, Information
Onglyza (saxagliptin) was approved by the U.S. Food and Drug Administration in 2009 as a DPP-4 inhibitor created by AstraZeneca to combat the effects of type 2 diabetes.
Onglyza (saxagliptin) was designed by AstraZeneca to help control blood sugar in those who suffer from type 2 diabetes and was approved for this use by the U.S. Food and Drug Administration in 2009.
Developed by AstraZeneca and approved by the U.S. Food and Drug Administration in 2009, Onglyza (saxagliptin) was designed to control blood sugar in those suffering from type two diabetes.
While hailed as an effective drug-class to combat type 2 diabetes, the FDA has discovered that many DPP-4 inhibitors, including Onglyza, can often heighten the risk of consumers getting a heart attack
A list of the 22 largest settlements reached between the United States Department of Justice and pharmaceutical companies from 1991 to 2013, ordered by the size of the total settlement.
You may have recently seen an advertisement on television about Onglyza and the potential complications that are caused by taking the dangerous drug. These commercials are airing because recent studies have identified this drug to have potentially dangerous and life threatening side effects, including heart attacks. Several lawsuits have been filed in the past few […]
SAN JOSE — The U.S. Food and Drug Administration has indicated that Onglyza and other diabetes drugs can cause severe and debilitating joint pain in drug users.
SILVER SPRING, Md. — The U.S. Food and Drug Administration has issued a safety communication detailing the risk of heart failure associated with the type 2 diabetes drug, Onglyza.
Type 2 diabetes drugs categorized as DPP-4 inhibitors have been reported to carry an increase risk of cancer metastasis according to a study tested on mice. According to Diabetes.co.uk, the study involved Januvia (sitagliptin) and Onglyza (saxagliptin) being exposed to the test mice. The tests showed an increase in cancer metastasis, but did not show an […]